Patents by Inventor Hayat Bahr-Mahmud

Hayat Bahr-Mahmud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA COMPOSITIONS TARGETING CLAUDIN-18.2
    Publication number: 20240043527
    Abstract: The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g, but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g, in combination with a chemotherapeutic agent).
    Type: Application
    Filed: March 29, 2021
    Publication date: February 8, 2024
    Inventors: Ugur Sahin, Claudia Lindemann, Jan Diekmann, Kerstin Brettschneider, Hayat Bähr-Mahmud, Ursula Ellinghaus, Leyla Fischer, Christiane Stadler, Özlem Türeci
  • Agents for Treatment of Claudin Expressing Cancer Diseases
    Publication number: 20200399370
    Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: June 11, 2020
    Publication date: December 24, 2020
    Inventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Agents for treatment of claudin expressing cancer diseases
    Patent number: 10717780
    Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 21, 2020
    Assignees: BioNTech AG, Ganymed Pharmaceuticals GmbH, TRON—Translationale Onkologic an der Universitätsmedzin der Johannes Gutenberg-Universität Mainz gemcinnützige GmbH
    Inventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Agents for Treatment of Claudin Expressing Cancer Diseases
    Publication number: 20190055311
    Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 21, 2019
    Inventors: Ugur Sahin, Ozlem Türeci, Christiane Stadler, Julia Holland, Hayat Bähr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Agents for treatment of claudin expressing cancer diseases
    Patent number: 10093736
    Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: October 9, 2018
    Assignees: BIONTECH AG, TRON GGMBH, UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Agents for Treatment of Claudin Expressing Cancer Diseases
    Publication number: 20160272711
    Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: November 12, 2013
    Publication date: September 22, 2016
    Inventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler